Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at under registration no. NCT00901940.).

Original publication




Journal article


Clin Vaccine Immunol

Publication Date





1164 - 1168


Adult, Aged, Antibodies, Bacterial, Antigens, Bacterial, Female, Humans, Male, Meningitis, Meningococcal, Meningococcal Vaccines, Middle Aged, Neisseria meningitidis, Polysaccharides, Bacterial, United Kingdom, Vaccination, Vaccines, Conjugate, Young Adult